Vor Bio Advances Telitacicept Trials with $514M Cash Runway into 2029 — Vor Biopharma Inc. (Vor Bio)

Event summary

Vor Bio reports $514.5M pro-forma cash position, sufficient for operations into early 2029.
Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis (gMG) on track for topline results in 1H 2027.
Phase 3 UPSTREAM SjD trial for primary Sjögren’s disease ongoing with no set timeline for results.
Telitacicept received two additional commercial approvals in China for Sjögren’s disease and IgA nephropathy.

The big picture

Vor Bio’s progress with telitacicept underscores the growing interest in dual BAFF/APRIL inhibitors for autoimmune diseases. The company’s ability to secure regulatory approvals and complete pivotal trials will be critical in differentiating itself in a competitive landscape. With a strong cash position, Vor Bio has the financial flexibility to pursue multiple indications, but must demonstrate clinical efficacy to attract potential partners or buyers.

What we're watching

Regulatory Momentum: Whether Vor Bio can secure additional regulatory approvals for telitacicept in the U.S. and Europe, following its success in China.
Trial Execution: The pace at which Vor Bio completes enrollment and generates topline data from the UPSTREAM MG trial in 1H 2027.
Financial Strategy: How Vor Bio plans to extend its cash runway beyond early 2029, given its current burn rate and lack of revenue.